With over 402,000 Chikungunya virus (CHIKV) cases and 180 related deaths already reported this year in the Region of the Americas, a team of vaccine experts today presented very positive seroresponse rate data of the only approved vaccine.
On October 23, 2024, Susan Hills, MBBS MTH CDC Lead, Chikungunya Vaccines Work Group Arboviral Diseases Branch Division of Vector-Borne Diseases, led a review of the IXCHIQ® vaccine.
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
